Galindo Alejandro
SEC CIK 1821447 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MNKD | MANNKIND CORP | EVP Endocrine Business Unit | 777.1K | $142.7K | $17.8K | 13 | 2021-07-30 | 2022-08-22 |
Most active insiders at MNKD, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Castagna Michael | CEO, Dir | $259.0K | $1.25M |
| 2 | Thomson David | EVP Genl Counsel, Sec | — | $930.8K |
| 3 | Binder Steven B. | Dir | — | $555.2K |
| 4 | Tross Stuart A | Chief People, Workpl Off | — | $297.5K |
| 5 | Singh Sanjay R | EVP Technical Ops | — | $94.4K |
| 6 | Ahuja Ajay | Chief Medical Off | — | — |
| 7 | Marasco Dominic | Pres, Endocrine Business Unit | — | — |
| 8 | Prentiss Christopher B | CFO | — | — |
| 9 | Shannon James Samuel | Dir | — | — |
| 10 | HOOPER ANTHONY C | Dir | — | — |
Galindo Alejandro made no open-market trades at MNKD in the last 12 months.
Transactions 13
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-08-24 | 2022-02-28 | MNKD | MANNKIND CORP | Galindo Alejandro | EVP Endocrine Business Unit | A - Grant | $2.71 | +36.9K | 576.7K | +7% | +$100.0K |
| A | 2022-08-24 | 2022-01-31 | MNKD | MANNKIND CORP | Galindo Alejandro | EVP Endocrine Business Unit | A - Grant | $3.17 | +1,804 | 539.8K | +0.3% | +$5,719 |
| A | 2022-08-24 | 2022-07-31 | MNKD | MANNKIND CORP | Galindo Alejandro | EVP Endocrine Business Unit | A - Grant | $2.93 | +5,000 | 781.7K | +0.6% | +$14.7K |
| M | 2022-08-23 | 2022-08-22 | MNKD | MANNKIND CORP | Galindo Alejandro | EVP Endocrine Business Unit | S - Sale | $3.85 | -4,615 | 777.1K | -0.6% | -$17.8K |
| 2022-08-01 | 2022-07-31 | MNKD | MANNKIND CORP | Galindo Alejandro | EVP Endocrine Business Unit | P - Purchase | $2.93 | +5,000 | 781.7K | +0.6% | +$14.7K | |
| A | 2022-05-25 | 2022-05-18 | MNKD | MANNKIND CORP | Galindo Alejandro | EVP Endocrine Business Unit | I - Discretionary | $3.19 | +4,789 | 776.7K | +0.6% | +$15.3K |
| 2022-05-20 | 2022-05-18 | MNKD | MANNKIND CORP | Galindo Alejandro | EVP Endocrine Business Unit | F - Tax | $3.19 | -4,789 | 771.9K | -0.6% | -$15.3K | |
| M | 2022-05-12 | 2022-05-10 | MNKD | MANNKIND CORP | Galindo Alejandro | EVP Endocrine Business Unit | A - Grant | $0.00 | +200.0K | 666.7K | +43% | $0 |
| 2022-03-01 | 2022-02-28 | MNKD | MANNKIND CORP | Galindo Alejandro | Chief Commercial Off | P - Purchase | $2.71 | +36.9K | 576.7K | +7% | +$100.0K | |
| A | 2022-02-09 | 2022-01-31 | MNKD | MANNKIND CORP | Galindo Alejandro | Chief Commercial Off | P - Purchase | $3.17 | +1,804 | 539.8K | +0.3% | +$5,719 |
| 2022-02-02 | 2022-01-31 | MNKD | MANNKIND CORP | Galindo Alejandro | Chief Commercial Off | P - Purchase | $3.17 | +2,334 | 540.3K | +0.4% | +$7,399 | |
| 2021-08-27 | 2021-08-27 | MNKD | MANNKIND CORP | Galindo Alejandro | Chief Commercial Off | F - Tax | $4.91 | -9,616 | 538.0K | -2% | -$47.2K | |
| 2021-08-02 | 2021-07-30 | MNKD | MANNKIND CORP | Galindo Alejandro | Chief Commercial Off | P - Purchase | $2.99 | +5,000 | 547.6K | +0.9% | +$15.0K |
Purchase Sale Sale after option exercise All abbreviations